Of particular concern is the price of the UN World Health Organization-recommended third-line drug raltegravir – an integrase inhibitor that blocks retroviral replication – which costs up to US $5,870 per person per year in Brazil, compared with $675 in sub-Saharan Africa. ❋ Unknown (2011)
The study conducted at UNSW's National Centre in HIV Epidemiology and Clinical Research (NCHECR), shows that the majority of patients who have not responded to traditional retroviral treatments will have good results from a new combination therapy involving raltegravir. ❋ Unknown (2008)
MSD, had in a statement disclosed that its HIV drug, Isentress (raltegravir), was approved by US FDA in October 2007, and that the National Health Research and Ethics Committee (NHREC) and National Agency for Food and Drug Administration and Control (NAFDAC) have given their approval to the local study. ❋ Unknown (2008)
Merck & Co, Inc., the manufacturer of raltegravir, supported both studies. ❋ Unknown (2008)
It has also been observed that raltegravir lowers the amount of virus in the blood to undetectable levels in 62 percent of the people taking it in combination with other anti-HIV medicines. ❋ Unknown (2008)
The drugs raltegravir and elvitegravir are called integrase inhibitors, which target HIV by inhibiting from using integrase, one of the three enzymes the virus uses to replicate itself in CD4 immune cells. ❋ Ron Buckmire (2007)
The new drugs are Pfizer's maraviroc, Merck's raltegravir and Gilead's elvitegravir who thinks up these names? ❋ Ron Buckmire (2007)
Isentress, known generically as raltegravir, would be the first drug on the market to target a third enzyme -- integrase -- that helps the virus insert its DNA into that of human cells. ❋ Unknown (2007)
The data demonstrated that the firm's oral HIV integrase inhibitor elvitegravir in treatment-experienced patients was non-inferior to the integrase inhibitor raltegravir.
Isentress raltegravir is a synthetic oligonucleotide that blocks the integration of HIV into the cell.
In drug interaction studies, raltegravir did not have a clinically meaningful effect on the pharmacokinetics of the following: hormonal contraceptives, methadone, lamivudine, tenofovir, etravirine and darunavir/ritonavir.
Coadministration of ISENTRESS with drugs that inhibit UGT1A1 may increase plasma levels of raltegravir.
Coadministration of ISENTRESS with drugs that are strong inducers of uridine diphosphate glucuronosyltransferase UGT 1A1 may result in reduced plasma concentrations of raltegravir.
ISENTRESS raltegravir, an HIV integrase inhibitor for use in combination with other antiretroviral agents for the treatment of HIV-1 infection, reported worldwide sales of $313 million for the fourth quarter of 2010, an increase of 34 percent compared with the fourth quarter of 2009.
Turnover from the HIV drug Isentress (raltegravir) reached $234 million, up 80%, while sales of the cervical cancer jab Gardasil slipped 3% to $277 million. ❋ Unknown (2010)
ISENTRESS (raltegravir), an HIV integrase inhibitor for use in combination with other antiretroviral agents for the treatment of HIV-1 infection, reported worldwide sales of $234 million for the fourth quarter of 2009, an increase of 80 percent compared with the fourth quarter of 2008. ❋ Unknown (2010)
CD4-positive cell counts continued to rise in both groups through week 192, Gotuzzo noted, so that there was a 295-cell increase among the raltegravir patients and a 274-cell increase from baseline among efavirenz patients. ❋ Unknown (2010)
